Single User
£3750
PDF
52 pages

Acute Decompensated Heart Failure in 12 Major Markets 2017-2027


Acute decompensated heart failure (ADHF), a sub-set of chronic heart failure (CHF), is a life-threatening episode during which the heart is not able to supply sufficient blood flow to the body. This requires urgent medical attention. The condition is divided into two subtypes: ADHF with reduced (ADHF-REF) and preserved (ADHF-PEF) ejection fraction. HF is characterized by dyspnoea at rest or on exertion and worsening fluid retention, apparent as lung congestion and/or swollen ankles and legs.

This report provides the current prevalent population for ADHF across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Japan, China, Russia, Brazil, India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, ADHF-REF and ADHF-PEF patients have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Moreover, a forecast of ADHF patient populations demonstrating main comorbidities has been included.

Main co-morbidities for ADHF include:

  • Diabetes
  • COPD
  • Anaemia
  • Atrial fibrillation
  • Coronary artery disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global ADHF market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of ADHF and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on ADHF prevalent population.
  • Identify sub-populations within ADHF which require treatment.
  • Gain an understanding of the specific markets that have the largest number of ADHF patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR ACUTE DECOMPENSATED HEART FAILURE
  • ACUTE DECOMPENSATED HEART FAILURE WITH REDUCED EJECTION FRACTION
  • COMORBID CONDITIONS OF ADHF-REF PATIENTS
  • ACUTE DECOMPENSATED HEART FAILURE WITH PRESERVED EJECTION FRACTION
  • COMORBID CONDITIONS OF ADHF-PEF PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN ANALYSIS PUBLICATIONS
  • BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES
  • PATIENT-BASED OFFERING
  • ONLINE PRICING DATA & PLATFORMS
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Causes and Precipitating Factors of Acute Heart Failure
  • Table 2. Classification and Common Clinical Characteristics of Patients with Acute Heart Failure
  • Table 3. NYHA Classification of Heart Failure
  • Table 4. Clinical-hemodynamic profiles of heart failure (following Stevenson et al.)
  • Table 5. Prevalence of Acute Decompensated Heart Failure, total (000s)
  • Table 6. Prevalence of Acute Decompensated Heart Failure, males (000s)
  • Table 7. Prevalence of Acute Decompensated Heart Failure, females (000s)
  • Table 8. Prevalence of ADHF-REF, total (000s)
  • Table 9. Prevalence of ADHF-REF, males (000s)
  • Table 10. Prevalence of ADHF-REF, females (000s)
  • Table 11. ADHF-REF Patients with Diabetes, total (000s)
  • Table 12. ADHF-REF Patients with COPD, total (000s)
  • Table 13. ADHF-REF Patients with Anaemia, total (000s)
  • Table 14. ADHF-REF Patients with Atrial Fibrillation, total (000s)
  • Table 15. ADHF-REF Patients with Coronary Artery Disease, total (000s)
  • Table 16. Prevalence of ADHF-PEF, total (000s)
  • Table 17. Prevalence of ADHF-PEF, males (000s)
  • Table 18. Prevalence of ADHF-PEF, females (000s)
  • Table 19. ADHF-PEF Patients with Diabetes, total (000s)
  • Table 20. ADHF-PEF Patients with COPD, total (000s)
  • Table 21. ADHF-PEF Patients with Anaemia, total (000s)
  • Table 22. ADHF-PEF Patients with Atrial Fibrillation, total (000s)
  • Table 23. ADHF-PEF Patients with Coronary Artery Disease, total (000s)
  • Table 24. Abbreviations and Acronyms used in the report
  • Table 25. USA Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 26. USA Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 27. Canada Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 28. Canada Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 29. France Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 30. France Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 31. Germany Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 32. Germany Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 33. Italy Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 34. Italy Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 35. Spain Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 36. Spain Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 37. UK Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 38. UK Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 39. Japan Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 40. Japan Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 41. China Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 42. China Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 43. Russia Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 44. Russia Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 45. Brazil Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 46. Brazil Prevalence of ADHF by 5-yr age cohort, females (000s)
  • Table 47. India Prevalence of ADHF by 5-yr age cohort, males (000s)
  • Table 48. India Prevalence of ADHF by 5-yr age cohort, females (000s)
Brazil, Canada, China, France, Germany, India, Italy, Japan, Russian Federation, Spain, United Kingdom, United States of America